Oddo BHF Asset Management Sas Acquires New Holdings in CureVac N.V. $CVAC

Oddo BHF Asset Management Sas acquired a new stake in CureVac N.V. (NASDAQ:CVAC) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 650,557 shares of the company’s stock, valued at approximately $2,941,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC grew its stake in CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after acquiring an additional 3,000 shares during the last quarter. L2 Asset Management LLC grew its stake in CureVac by 38.5% in the 4th quarter. L2 Asset Management LLC now owns 19,756 shares of the company’s stock valued at $89,000 after acquiring an additional 5,495 shares during the last quarter. Headlands Technologies LLC acquired a new stake in CureVac in the 2nd quarter valued at about $35,000. Legal & General Group Plc grew its stake in CureVac by 7.3% in the 2nd quarter. Legal & General Group Plc now owns 123,250 shares of the company’s stock valued at $661,000 after acquiring an additional 8,411 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in CureVac in the 4th quarter valued at about $79,000. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Stock Performance

NASDAQ CVAC opened at $4.66 on Wednesday. CureVac N.V. has a fifty-two week low of $3.13 and a fifty-two week high of $5.72. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of 6.47 and a beta of 1.77. The business has a fifty day moving average of $4.66 and a 200-day moving average of $4.68. The company has a quick ratio of 3.69, a current ratio of 3.70 and a debt-to-equity ratio of 0.03.

CureVac Profile

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.